Your browser doesn't support javascript.
Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters.
Nouailles, Geraldine; Adler, Julia M; Pennitz, Peter; Peidli, Stefan; Teixeira Alves, Luiz Gustavo; Baumgardt, Morris; Bushe, Judith; Voss, Anne; Langenhagen, Alina; Langner, Christine; Martin Vidal, Ricardo; Pott, Fabian; Kazmierski, Julia; Ebenig, Aileen; Lange, Mona V; Mühlebach, Michael D; Goekeri, Cengiz; Simmons, Szandor; Xing, Na; Abdelgawad, Azza; Herwig, Susanne; Cichon, Günter; Niemeyer, Daniela; Drosten, Christian; Goffinet, Christine; Landthaler, Markus; Blüthgen, Nils; Wu, Haibo; Witzenrath, Martin; Gruber, Achim D; Praktiknjo, Samantha D; Osterrieder, Nikolaus; Wyler, Emanuel; Kunec, Dusan; Trimpert, Jakob.
  • Nouailles G; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Adler JM; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Pennitz P; Institut für Virologie, Freie Universität Berlin, Berlin, Germany.
  • Peidli S; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Teixeira Alves LG; Institute of Pathology Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Institute for Biology, IRI Life Sciences, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Baumgardt M; Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
  • Bushe J; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Voss A; Institut für Tierpathologie, Freie Universität Berlin, Berlin, Germany.
  • Langenhagen A; Institut für Tierpathologie, Freie Universität Berlin, Berlin, Germany.
  • Langner C; Institut für Tierpathologie, Freie Universität Berlin, Berlin, Germany.
  • Martin Vidal R; Institut für Virologie, Freie Universität Berlin, Berlin, Germany.
  • Pott F; Institut für Virologie, Freie Universität Berlin, Berlin, Germany.
  • Kazmierski J; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Ebenig A; Berlin Institute of Health (BIH), Berlin, Germany.
  • Lange MV; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Mühlebach MD; Berlin Institute of Health (BIH), Berlin, Germany.
  • Goekeri C; Product Testing of IVMPs, Division of Veterinary Medicines, Paul-Ehrlich-Institut, Langen, Germany.
  • Simmons S; Product Testing of IVMPs, Division of Veterinary Medicines, Paul-Ehrlich-Institut, Langen, Germany.
  • Xing N; Product Testing of IVMPs, Division of Veterinary Medicines, Paul-Ehrlich-Institut, Langen, Germany.
  • Abdelgawad A; German Center for Infection Research (DZIF), partner site Gießen-Marburg-Langen, Giessen, Germany.
  • Herwig S; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Cichon G; Faculty of Medicine, Cyprus International University, Nicosia, Cyprus.
  • Niemeyer D; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Drosten C; Institut für Virologie, Freie Universität Berlin, Berlin, Germany.
  • Goffinet C; Institut für Virologie, Freie Universität Berlin, Berlin, Germany.
  • Landthaler M; Department of Gynecology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Blüthgen N; Department of Gynecology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Wu H; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Witzenrath M; German Center for Infection Research (DZIF), partner site Charité, Berlin, Germany.
  • Gruber AD; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Praktiknjo SD; German Center for Infection Research (DZIF), partner site Charité, Berlin, Germany.
  • Osterrieder N; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Wyler E; Berlin Institute of Health (BIH), Berlin, Germany.
  • Kunec D; Berlin Institute for Medical Systems Biology (BIMSB) Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), and Institute for Biology, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Trimpert J; Institute of Pathology Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Institute for Biology, IRI Life Sciences, Humboldt-Universität zu Berlin, Berlin, Germany.
Nat Microbiol ; 8(5): 860-874, 2023 05.
Article in English | MEDLINE | ID: covidwho-2274440
ABSTRACT
Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Nat Microbiol Year: 2023 Document Type: Article Affiliation country: S41564-023-01352-8

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Nat Microbiol Year: 2023 Document Type: Article Affiliation country: S41564-023-01352-8